Fate Therapeutics (FATE) Competitors $1.16 +0.01 (+0.87%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.16 0.00 (-0.09%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. SEPN, SIGA, ATYR, PGEN, MREO, CAPR, KMDA, RAPP, CGEM, and PRTCShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Septerna (SEPN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Precigen (PGEN), Mereo BioPharma Group (MREO), Capricor Therapeutics (CAPR), Kamada (KMDA), Rapport Therapeutics (RAPP), Cullinan Therapeutics (CGEM), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Septerna Siga Technologies aTyr Pharma Precigen Mereo BioPharma Group Capricor Therapeutics Kamada Rapport Therapeutics Cullinan Therapeutics PureTech Health Fate Therapeutics (NASDAQ:FATE) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Do insiders and institutionals have more ownership in FATE or SEPN? 97.5% of Fate Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, FATE or SEPN? Septerna has lower revenue, but higher earnings than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.75-$186.26M-$1.49-0.78Septerna$1.08M481.91-$71.80MN/AN/A Do analysts recommend FATE or SEPN? Fate Therapeutics currently has a consensus target price of $3.83, suggesting a potential upside of 230.46%. Septerna has a consensus target price of $26.75, suggesting a potential upside of 129.02%. Given Fate Therapeutics' higher possible upside, equities analysts plainly believe Fate Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer FATE or SEPN? In the previous week, Fate Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Fate Therapeutics and 3 mentions for Septerna. Fate Therapeutics' average media sentiment score of 0.72 beat Septerna's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is FATE or SEPN more profitable? Septerna has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Septerna's return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% Septerna N/A N/A N/A SummarySepterna beats Fate Therapeutics on 7 of the 13 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.79M$2.96B$5.55B$9.04BDividend YieldN/A2.43%5.25%4.04%P/E Ratio-0.7821.1127.2020.14Price / Sales9.75251.53413.3398.20Price / CashN/A42.7337.5058.41Price / Book0.417.748.085.60Net Income-$186.26M-$54.96M$3.16B$248.43M7 Day Performance1.31%9.10%4.68%5.47%1 Month Performance-25.16%5.73%4.49%7.87%1 Year Performance-65.88%2.79%30.99%18.75% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.288 of 5 stars$1.16+0.9%$3.83+230.5%-62.8%$131.79M$13.63M-0.78550SEPNSepterna1.1799 of 5 stars$10.85-4.6%$26.75+146.5%N/A$483.45M$977K0.00N/ASIGASiga Technologies1.5149 of 5 stars$6.73+0.6%N/A-19.1%$480.80M$120.33M10.0440News CoverageOptions VolumeATYRaTyr Pharma2.5008 of 5 stars$5.30-0.2%$20.20+281.1%N/A$471.72MN/A-6.5453Gap DownHigh Trading VolumePGENPrecigen4.2871 of 5 stars$1.59-1.9%$6.00+277.4%+24.0%$469.34M$3.92M-2.84190MREOMereo BioPharma Group2.2613 of 5 stars$2.92+1.7%$7.60+160.3%-55.2%$464.28M$10M-41.7140News CoverageAnalyst ForecastGap DownHigh Trading VolumeCAPRCapricor Therapeutics3.4346 of 5 stars$9.90-3.4%$32.22+225.5%+147.8%$452.23M$22.27M-6.97101KMDAKamada3.7092 of 5 stars$7.71-2.2%$13.00+68.6%+35.9%$443.40M$160.95M26.59360RAPPRapport Therapeutics1.9585 of 5 stars$12.04flat$28.00+132.6%-35.5%$439.44MN/A-3.49N/AAnalyst ForecastCGEMCullinan Therapeutics1.9457 of 5 stars$7.42-5.0%$30.00+304.3%-51.1%$437.89MN/A-2.5530News CoveragePRTCPureTech Health2.0811 of 5 stars$18.01flat$45.00+149.9%-26.8%$432.60M$4.83M0.00100News CoverageGap Down Related Companies and Tools Related Companies Septerna Alternatives Siga Technologies Alternatives aTyr Pharma Alternatives Precigen Alternatives Mereo BioPharma Group Alternatives Capricor Therapeutics Alternatives Kamada Alternatives Rapport Therapeutics Alternatives Cullinan Therapeutics Alternatives PureTech Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
